🚀 VC round data is live in beta, check it out!
Voronoi Valuation Multiples
Discover revenue and EBITDA valuation multiples for Voronoi and similar public comparables like Ajanta Pharma, Camurus, Travere Therapeutics, Zhejiang Huahai and more.
Voronoi Overview
About Voronoi
Voronoi Inc is a biotech company that develops novel kinase inhibitors and targets protein degraders. It is principally focused on developing targeted therapies for anticancer drugs such as lung and breast cancer. Its pipeline products are: VRN11, VRN16, VRN10, VRN19, VRN07, VRN04, VRN06, and others.
Founded
2015
HQ
Employees
147
Website
Sectors
Financials (FY)
EV
$4B
Voronoi Financials
Voronoi reported last fiscal year revenue of $5M and negative EBITDA of ($31M).
In the same fiscal year, Voronoi generated $5M in gross profit, ($31M) in EBITDA losses, and had net loss of ($29M).
Revenue (LTM)
Voronoi P&L
In the most recent fiscal year, Voronoi reported revenue of $5M and EBITDA of ($31M).
Voronoi expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $5M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $5M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 100% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($31M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (615%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (724%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($29M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (568%) | XXX | XXX | XXX |
| Net Debt | — | — | $1M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Voronoi Stock Performance
Voronoi has current market cap of $4B, and enterprise value of $4B.
Market Cap Evolution
Voronoi's stock price is $207.72.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4B | $4B | 1.7% | XXX | XXX | XXX | $-1.61 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialVoronoi Valuation Multiples
Voronoi trades at 722.4x EV/Revenue multiple, and (117.5x) EV/EBITDA.
EV / Revenue (LTM)
Voronoi Financial Valuation Multiples
As of April 18, 2026, Voronoi has market cap of $4B and EV of $4B.
Equity research analysts estimate Voronoi's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Voronoi has a P/E ratio of (129.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 722.4x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (117.5x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (99.8x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 722.4x | XXX | XXX | XXX |
| P/E | — | XXX | (129.3x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (73.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Voronoi Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Voronoi Margins & Growth Rates
Voronoi's revenue in the last fiscal year grew by —.
Voronoi's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.3M for the same period.
Voronoi Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Margin | — | XXX | (615%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 53% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 35% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 25% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 413% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 824% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Voronoi Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Voronoi | XXX | XXX | XXX | XXX | XXX | XXX |
| Ajanta Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Camurus | XXX | XXX | XXX | XXX | XXX | XXX |
| Travere Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Zhejiang Huahai | XXX | XXX | XXX | XXX | XXX | XXX |
| ACADIA Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Voronoi M&A Activity
Voronoi acquired XXX companies to date.
Last acquisition by Voronoi was on XXXXXXXX, XXXXX. Voronoi acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Voronoi
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialVoronoi Investment Activity
Voronoi invested in XXX companies to date.
Voronoi made its latest investment on XXXXXXXX, XXXXX. Voronoi invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Voronoi
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Voronoi
| When was Voronoi founded? | Voronoi was founded in 2015. |
| Where is Voronoi headquartered? | Voronoi is headquartered in South Korea. |
| How many employees does Voronoi have? | As of today, Voronoi has over 147 employees. |
| Who is the CEO of Voronoi? | Voronoi's CEO is Hyun-Tae Kim. |
| Is Voronoi publicly listed? | Yes, Voronoi is a public company listed on Korea Exchange. |
| What is the stock symbol of Voronoi? | Voronoi trades under 310210 ticker. |
| When did Voronoi go public? | Voronoi went public in 2022. |
| Who are competitors of Voronoi? | Voronoi main competitors are Ajanta Pharma, Camurus, Travere Therapeutics, Zhejiang Huahai. |
| What is the current market cap of Voronoi? | Voronoi's current market cap is $4B. |
| What is the current revenue of Voronoi? | Voronoi's last fiscal year revenue is $5M. |
| What is the current EV/Revenue multiple of Voronoi? | Current revenue multiple of Voronoi is 722.4x. |
| Is Voronoi profitable? | No, Voronoi is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.